Continued Brand Name Victoza Shortages
- Details
- Published: Monday, 26 May 2025 11:40
- Written by Sara Jones
Our teams report that they are receiving pharmacy notifications for Victoza shortages. This is largely affecting those patients who fill the medication through 340B. The estimated resolution is mid to late July, but as we all know it can often take longer to resolve. Unfortunately, the generic (liraglutide) is not affordably priced through 340b currently (250$-350$ per month). You will likely be receiving tasks notifying you of these shortages as they come up. We are encouraging patients to call other Safeway and Walgreens locations in town to check if they have BRAND Victoza in stock and transfer the prescription if possible.
Estimated Resupply Dates
Novo Nordisk has Victoza 6 mg/mL 3 mL pens in 2 and 3 count presentations on back order and the company estimates a release date of mid-July 2025.
Products Affected - Description
Victoza subcutaneous injection, Novo Nordisk, 6 mg/mL, 3 mL pen injector, 2 count, NDC 00169-4060-12
Victoza subcutaneous injection, Novo Nordisk, 6 mg/mL, 3 mL pen injector, 3 count, NDC 00169-4060-13
Reason for the Shortage
Meitheal launched liraglutide injection in April 2025.
Novo Nordisk has Victoza on shortage due to manufacturing delays.
Novo Nordisk has Saxenda available.
Teva launched the authorized generic of liraglutide in late-June 2024.
Other Options for GLP1 coverage include:
For Medicare Part D patients, we can explore patient assistance programs.
Many of these patients have been on Victoza through 340b for a long time:
- if they have commercial insurance, it might be worth checking to see if their coverage has changed and if copay is affordable for any of the GLP1 agonists. There are commercial copay cards they can use as well.
- If they have Pacific source, the PA criteria has softened in the last couple years and it might be worth reviewing to see if they qualify. The generic liraglutide is preferred at this time.
Pacific Source PA requires documentation of all the following for liraglutide. Liraglutide must be tried for 3 months before approval of Trulicity or Ozempic.
Inadequate treatment response, intolerance, or contraindication to metformin
PLUS - Documented failure of an antidiabetic agent other than metformin (e.g., Steglatro, alogliptin, pioglitazone)
PLUS - Recent A1C level greater than 7% despite treatment (patient cannot be currently untreated
Please reach out to myself or Medication Access for questions about insurance coverage. I will pass along more information as it becomes available on the shortage.